You are here

FDA Approves IND Application for RP-A501 for Danon Disease

First Investigational Gene Therapy for Monogenic Heart Failure Syndrome

RP-A501 is Rocket Pharmaceuticals’ first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease.

Danon disease is a life-threatening heart-failure syndrome that develops during childhood and adolescence. The rare neuromuscular and cardiovascular disease is associated with severe cardiomyopathy, skeletal myopathies, and mild cognitive impairment.

Between 15,000 and 30,000 patients in the U.S. and Europe are estimated to have Danon disease. It is often fatal by the time patients reach their twenties or thirties as a result of progressive heart failure unless it is treated with a cardiac transplantation. However, this is not curative.

Rocket Pharmaceuticals plans to publish a comprehensive literature review of Danon cases and conduct a retrospective chart review in conjunction with the phase 1 clinical trial, which is expected to begin after June 2019.

Source: Rocket Pharmaceuticals, January 22, 2019

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
First Medicines for Adults With Wild-type or Hereditary ATTR-CM